Publication Name	World Journal of Gastroenterology
Manuscript ID	3571
Country	China

Received	2013-05-07 08:46
Peer-Review Started	2013-05-07 10:57
To Make the First Decision	2013-07-05 18:31
Return for Revision	2013-07-17 10:34
Revised	2013-08-13 00:19
Second Decision	2013-09-13 14:56
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2013-09-13 22:43
Articles in Press
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2013-10-17 10:34
Publish the Manuscript Online	2013-11-13 08:37

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Autobiography
Article Title	Antiviral therapy delays esophageal variceal bleeding in hepatitis B virus-related cirrhosis
Manuscript Source	Invited Manuscript
All Author List	Chang-Zheng Li, Liu-Fang Cheng, Qing-Shan Li, Zhi-Qiang Wang and Jun-Hong Yan
Funding Agency and Grant Number
Corresponding Author	Chang-Zheng Li, MD, Department of Gastroenterology and Hepatology, Institute of Hepatobiliary and Gastrointestinal Diseases, Chinese Second Artillery General Hospital, No. 16, Xinjiekouwai Street, Xicheng District, Beijing 100088, China. licz007@aliyun.com
Key Words	Nucleoside analog; Esophageal variceal bleeding; Hepatitis B virus; Cirrhosis; Resistance; Entecavir; Lamivudine; Adefovir
Core Tip	Antiviral therapy with nucleoside analogs improves clinical outcome in hepatitis B virus (HBV)-related decompensated cirrhosis. However, the emergence of resistance results in liver injury. The consequences may be worse in patients with esophageal varices (EV), in which bleeding and death often occur. This study evaluated the efficacy of antiviral treatment over 5 years in patients with HBV-related cirrhosis and EV and found that antiviral therapy decreased the risk of bleeding. However, agents with a high rate of virological breakthrough were ineffective in preventing bleeding. These findings provide evidence-based suggestions for the treatment of this special group of patients.
Publish Date	2013-11-13 08:37
Citation	Li CZ, Cheng LF, Li QS, Wang ZQ, Yan JH. Antiviral therapy delays esophageal variceal bleeding in hepatitis B virus-related cirrhosis. World J Gastroenterol 2013; 19(40): 6849-6856
URL	http://www.wjgnet.com/1007-9327/full/v19/i40/6849.htm
DOI	http://dx.doi.org/10.3748/wjg.v19.i40.6849

Full Article (PDF)	WJG-19-6849.pdf
Manuscript File	3571-Review.doc
Answering Reviewers	3571-Answering reviewers.pdf
Copyright License Agreement	3571-Copyright assignment.doc
Non-Native Speakers of English Editing Certificate	3571-Language certificate.doc
Peer-review Report	3571-Peer reviewer(s).pdf
Scientific Editor Work List	3571-Scientific editor work list.doc